NASDAQ:ELDN Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis $2.74 +0.03 (+1.11%) Closing price 10/15/2025 04:00 PM EasternExtended Trading$2.75 +0.01 (+0.36%) As of 10/15/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Eledon Pharmaceuticals Stock (NASDAQ:ELDN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Eledon Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.68▼$2.8050-Day Range$2.37▼$2.9852-Week Range$2.32▼$5.54Volume2.14 million shsAverage Volume1.08 million shsMarket Capitalization$164.07 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingHold Company Overview Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders. Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications. Its lead candidate has advanced into initial human trials, and additional assets are in IND-enabling studies. To support development, the company collaborates with academic research institutions and specialty contract development organizations, drawing on external expertise for pharmacology, toxicology and clinical trial execution. Based in the United States with operations in Europe, Eledon Pharmaceuticals conducts multi-center studies across North America and the EMEA region. The company’s leadership team brings together experienced drug development professionals, clinical operations specialists and regulatory experts, positioning Eledon to advance its portfolio toward late-stage trials and eventual commercialization.AI Generated. May Contain Errors. Read More Eledon Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks39th Percentile Overall ScoreELDN MarketRank™: Eledon Pharmaceuticals scored higher than 39% of companies evaluated by MarketBeat, and ranked 718th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.0 / 5Analyst RatingHold Consensus RatingEledon Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 3 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialEledon Pharmaceuticals has a consensus price target of $10.00, representing about 265.0% upside from its current price of $2.74.Amount of Analyst CoverageEledon Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Eledon Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Eledon Pharmaceuticals are expected to decrease in the coming year, from ($0.81) to ($1.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eledon Pharmaceuticals is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eledon Pharmaceuticals is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEledon Pharmaceuticals has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Eledon Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.07% of the outstanding shares of Eledon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEledon Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Eledon Pharmaceuticals has recently increased by 25.12%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEledon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEledon Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.07% of the outstanding shares of Eledon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEledon Pharmaceuticals has a short interest ratio ("days to cover") of 6.2.Change versus previous monthShort interest in Eledon Pharmaceuticals has recently increased by 25.12%, indicating that investor sentiment is decreasing significantly. News and Social Media2.5 / 5News Sentiment0.41 News SentimentEledon Pharmaceuticals has a news sentiment score of 0.41. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Eledon Pharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 7 people have searched for ELDN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows7 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 250% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.30% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eledon Pharmaceuticals' insider trading history. Receive ELDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELDN Stock News HeadlinesHead-To-Head Review: Eledon Pharmaceuticals (NASDAQ:ELDN) & TELA Bio (NASDAQ:TELA)October 13 at 3:29 AM | americanbankingnews.comEledon Pharmaceuticals, Inc. (NASDAQ:ELDN) is largely controlled by institutional shareholders who own 51% of the companyOctober 9, 2025 | finance.yahoo.comNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning. | InvestorPlace (Ad)Eledon Pharmaceuticals to Participate in Plenary Session at 18th Congress of the International Xenotransplantation AssociationSeptember 24, 2025 | quiverquant.comQEledon Pharmaceuticals to Present at the 18th Congress of the International Xenotransplantation AssociationSeptember 24, 2025 | globenewswire.com2 ‘Strong Buy’ Stocks That Wall Street Believes Can Soar 360% to 780%September 23, 2025 | finance.yahoo.comEledon Pharmaceuticals to Participate in Cantor Global Healthcare Conference 2025August 29, 2025 | globenewswire.comCraig-Hallum Remains a Buy on Eledon Pharmaceuticals (ELDN)August 21, 2025 | theglobeandmail.comSee More Headlines ELDN Stock Analysis - Frequently Asked Questions How have ELDN shares performed this year? Eledon Pharmaceuticals' stock was trading at $4.12 at the start of the year. Since then, ELDN shares have decreased by 33.5% and is now trading at $2.74. How were Eledon Pharmaceuticals' earnings last quarter? Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.10. Who are Eledon Pharmaceuticals' major shareholders? Eledon Pharmaceuticals' top institutional shareholders include Brighton Jones LLC (0.07%) and Voya Investment Management LLC (0.02%). View institutional ownership trends. How do I buy shares of Eledon Pharmaceuticals? Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Eledon Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Eledon Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Arista Networks (ANET), ServiceNow (NOW), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/14/2025Today10/15/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELDN CIK1404281 Webnovustherapeutics.com Phone(949) 238-8090FaxN/AEmployees10Year FoundedN/APrice Target and Rating Average Price Target for Eledon Pharmaceuticals$10.00 High Price Target$12.00 Low Price Target$9.00 Potential Upside/Downside+265.0%Consensus RatingHold Rating Score (0-4)2.40 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$36.18 million Net MarginsN/A Pretax MarginN/A Return on Equity-92.51% Return on Assets-38.31% Debt Debt-to-Equity RatioN/A Current Ratio8.12 Quick Ratio8.12 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.05 per share Price / Book2.61Miscellaneous Outstanding Shares59,880,000Free Float52,517,000Market Cap$164.07 million OptionableOptionable Beta0.40 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:ELDN) was last updated on 10/16/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredGold to $27,533?This week, U.S. gold reserves hit an unprecedented $1 TRILLION in value... And it's sparking urgent chatter...Stansberry Research | SponsoredNvidia’s slow death marchEric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the righ...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eledon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
